Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and anti-mycobacterial activity of bedaquiline (TMC207) in children

extensively drug-resistant tuberculosis
tmc207
bedaquiline
pulmonary tuberculosis
chest x-ray
  • 140 views
  • 10 Aug, 2022
  • 5 locations
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB (DRAMATIC)

, the investigators will examine the efficacy and safety of an all-oral regimen of bedaquiline, delamanid, levofloxacin, linezolid, and clofazimine given for 16, 24, 32 or 40 weeks

  • 0 views
  • 10 Jul, 2022
  • 1 location
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China (PROSPECT)

The purpose of this study is to evaluate efficacy and safety of an oral bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) short-course regimen (SCR) compared to an oral SCR not

  • 0 views
  • 15 Jul, 2022
  • 2 locations
Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

This trial will assess the safety and efficacy of OPC-167832 combined with Delamanid and Bedaquiline in subjects with DS-TB administered for 4 months compared to rifampin, isoniazid, ethambutol

  • 0 views
  • 26 Jul, 2022
  • 7 locations
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

The purpose of this study is to assess the efficacy, safety and tolerability of a combination of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide treatments guided by PZA

  • 0 views
  • 29 Jan, 2021
  • 15 locations
Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081

This is a multi-center, randomized, parallel, open-label, positive-controlled Phase 2 clinical trial, which aims to evaluate the early bactericidal activity, safety and tolerability of WX-081 in patients with drug-naive&susceptible and drug-resistant tuberculosis. Also the efficacy of WX-081 will be explored in participants with drug-resistant tuberculosis.

  • 0 views
  • 22 Dec, 2021
  • 1 location
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial

PRACTECAL-PRO is a sub-study of a TB-PRACTECAL clinical trial for multidrug resistant Tuberculosis. It evaluates the effectiveness of TB-PRACTECAL interventions from the patient perspective in terms of their quality of life, shared decision making and satisfaction with services.

linezolid
bedaquiline
clofazimine
moxifloxacin
pretomanid
  • 2 views
  • 24 May, 2021
  • 7 locations
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) (endTB-Q)

endTB-Q Clinical Trial is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of two new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB) with fluoroquinolone resistance.

linezolid pill
fluoroquinolones
clofazimine
pulmonary tuberculosis
delamanid
  • 94 views
  • 11 Mar, 2022
  • 7 locations
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2) (BE-PEOPLE P2)

This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin

Accepts healthy volunteers
  • 0 views
  • 27 Jul, 2022
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

This trial is to describe the safety, tolerability and exposure-toxicity relationship of Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and Moxifloxacin

  • 0 views
  • 16 Nov, 2021
  • 7 locations